IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company's principal candidate includes INB-200, which are in clinical stage. IN8bio Inc. is based in New York.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-30.44M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.43 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -218.85% |
| Return on Assets (Trailing 12 Months) | -139.59% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.30 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.30 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.00 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.10 |
| Earnings per Share (Most Recent Fiscal Year) | $-16.52 |
| Diluted Earnings per Share (Trailing 12 Months) | $-13.57 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 3.02M |
| Free Float | 2.55M |
| Market Capitalization | $6.59M |
| Average Volume (Last 20 Days) | 0.42M |
| Beta (Past 60 Months) | 0.18 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 15.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 92.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |